Best Peptides for Energy and Fatigue

Best Peptides for Energy and Fatigue (2026)

Fatigue is not a single problem -- it is a symptom with at least four distinct biological mechanisms: mitochondrial dysfunction (your cells cannot produce enough ATP), hormonal decline (growth hormone, thyroid, testosterone deficits), sleep architecture disruption (insufficient deep sleep and REM), and metabolic inflexibility (impaired ability to switch between fuel sources). Treating "low energy" without identifying the underlying mechanism is why most supplements fail.

Peptide therapy offers targeted interventions for each of these mechanisms. Mitochondrial-targeted peptides like SS-31 and MOTS-c directly enhance the electron transport chain and cellular energy metabolism. Growth hormone secretagogues restore the anabolic and sleep-promoting effects of GH that decline with age. NAD+ precursors replenish the central cofactor that mitochondria need to produce ATP. And each approach works through a different enough pathway that they can be meaningfully combined.

This article ranks 5 peptides and peptide-related compounds for energy and fatigue by their mechanism, evidence strength, and the specific type of fatigue they address. Each section links to the full peptide page for detailed protocols.

Quick Comparison Table

1. MOTS-c -- Mitochondrial Exercise Mimetic

MOTS-c is a 16-amino-acid peptide encoded within the mitochondrial 12S rRNA gene that functions as an endogenous metabolic regulator. It represents the most direct pharmacological approach to the exercise-mimetic concept: enhancing cellular energy metabolism through the same AMPK-mediated pathways that physical activity activates, without requiring the physical activity itself.

The foundational study demonstrated that MOTS-c prevents high-fat-diet-induced obesity, reverses established insulin resistance, and enhances glucose metabolism in skeletal muscle through activation of the AMPK-AICAR pathway [1]. MOTS-c targets the same pathway that metformin activates (AMPK), but does so as a naturally occurring mitochondrial signal peptide rather than a synthetic pharmaceutical.

For energy and fatigue specifically, the exercise capacity data is compelling. MOTS-c treatment in both young and aged mice significantly enhanced physical performance, with the most striking results in older animals. Late-life MOTS-c treatment increased physical capacity and healthspan in aged mice, with adaptations similar to those seen in physically active animals: improved antioxidant capacity, better insulin sensitivity, and enhanced metabolic flexibility [2].

The human connection is established through exercise physiology research. Endogenous MOTS-c levels rise in skeletal muscle and circulation after physical activity, and this exercise-induced MOTS-c expression correlates with the metabolic benefits of exercise. This suggests MOTS-c plays a natural role in translating physical activity into metabolic improvement -- and that supplementation may partially replicate these benefits when exercise capacity is limited by fatigue, injury, or age.

The primary limitation is that large-scale human efficacy trials for energy and fatigue outcomes have not been completed. The biological rationale is strong, the animal data is consistent, and the endogenous role in exercise physiology is established -- but the clinical proof gap remains.

MOTS-c is administered via subcutaneous injection. For current evidence and protocols, see the MOTS-c page.

2. SS-31 (Elamipretide) -- Mitochondrial Membrane Stabilizer

SS-31 (also known as elamipretide) is a tetrapeptide that targets the inner mitochondrial membrane with remarkable specificity. It binds to cardiolipin, a phospholipid unique to the mitochondrial inner membrane, and stabilizes the electron transport chain complexes that produce ATP. This is the most direct intervention point for cellular energy production available in peptide form.

The energy-relevant evidence is substantial. In aged mice, 8 weeks of SS-31 treatment reversed age-related mitochondrial dysfunction, restored redox homeostasis, and improved exercise tolerance -- without increasing mitochondrial content [3]. This means SS-31 does not make more mitochondria; it makes existing mitochondria work better. The improvement in exercise capacity was achieved by normalizing proton leak (a major source of mitochondrial inefficiency in aging) and reducing mitochondrial reactive oxygen species production.

The cardiac data extends this principle to the most energy-demanding organ. Late-life SS-31 treatment substantially reversed cardiac dysfunction in old mice, normalizing the increase in proton leak and reducing mitochondrial ROS in cardiomyocytes [4]. This cardiac improvement has direct implications for exercise intolerance and fatigue -- cardiac output limitations are a primary contributor to exercise capacity decline with aging.

SS-31 also improved ADP sensitivity in aged mitochondria by increasing uptake through the adenine nucleotide translocator (ANT) [5]. ADP sensitivity is a critical determinant of how quickly mitochondria can ramp up ATP production in response to energy demand -- poor ADP sensitivity means sluggish energy responses during physical or mental exertion, which manifests as fatigue.

The clinical development of SS-31 has focused on mitochondrial diseases (Barth syndrome) and heart failure, where it has reached phase 2/3 trials. For age-related fatigue specifically, the preclinical evidence is the strongest available for any mitochondrial-targeted peptide, but human trials for this indication are needed.

SS-31 is administered via subcutaneous injection or intravenous infusion in clinical settings.

3. NAD+ Precursors (Nicotinamide Riboside / NMN)

NAD+ (nicotinamide adenine dinucleotide) is not a peptide, but NAD+ precursors are essential context for any discussion of energy peptides because NAD+ is the central cofactor that mitochondria require to produce ATP. Without adequate NAD+, even perfectly functioning mitochondria cannot generate energy efficiently. NAD+ levels decline approximately 50% between ages 40 and 60, making depletion a near-universal contributor to age-related fatigue.

Nicotinamide riboside (NR) has the strongest human clinical evidence. A randomized crossover study in older adults showed that acute NR supplementation improved isometric peak torque by 8% and the fatigue index by 15%, with increased NAD(P)H levels and decreased oxidative stress -- but these improvements were specific to older subjects and were not observed in young controls [6]. This specificity supports the hypothesis that NR works by correcting an age-related deficit rather than enhancing normal function.

Chronic supplementation consistently elevates NAD+ levels. In healthy middle-aged and older adults, NR supplementation raised NAD+ levels by 40-90% after 4-8 weeks in a dose-dependent manner [7]. The NAD+ elevation is sustained during continued supplementation and returns to baseline after discontinuation.

Skeletal muscle-specific effects are relevant for physical energy. A 21-day trial in aged men showed that 1 g NR per day elevated the muscle NAD+ metabolome and induced anti-inflammatory transcriptomic signatures. The anti-inflammatory component is notable because chronic low-grade muscle inflammation contributes to the fatigue-sarcopenia cycle in aging.

However, a long-COVID fatigue trial found that despite successfully raising NAD+ levels 2.6-3.1 fold, NR did not significantly improve fatigue, sleep, or mood versus placebo in that specific population. This suggests that NAD+ depletion may not be the primary driver of all fatigue subtypes, and that NAD+ restoration is most beneficial when NAD+ depletion is actually the limiting factor.

NAD+ precursors are taken orally at 300-1000 mg per day for NR, or 250-500 mg per day for NMN. They pair naturally with mitochondrial peptides (SS-31, MOTS-c) -- the precursors provide the cofactor, the peptides optimize how mitochondria use it.

4. CJC-1295/Ipamorelin -- Growth Hormone Secretagogue Combination

CJC-1295 and ipamorelin represent the most widely used injectable growth hormone secretagogue combination for fatigue related to hormonal decline. CJC-1295 is a long-acting growth hormone-releasing hormone (GHRH) analog that stimulates pulsatile GH release, while ipamorelin is a selective growth hormone secretagogue that amplifies GH pulses through the ghrelin receptor without the cortisol and prolactin spikes seen with older GH secretagogues.

The CJC-1295 clinical data is clear: a single injection produced dose-dependent increases in mean plasma GH concentrations by 2- to 10-fold for 6 or more days, and IGF-I levels by 1.5- to 3-fold for 9-11 days [8]. Critically, pulsatile GH secretion was preserved during continuous CJC-1295 stimulation, meaning it enhances the natural GH rhythm rather than replacing it with a flat, supraphysiologic level.

Ipamorelin's selectivity is its key advantage. Unlike GHRP-6 or GHRP-2, ipamorelin stimulates GH release without increasing cortisol, prolactin, or appetite -- side effects that would undermine an energy-focused protocol. The combination of GHRH-pathway (CJC-1295) and ghrelin-pathway (ipamorelin) stimulation produces synergistic GH amplification that exceeds either alone.

For energy and fatigue, the GH axis affects multiple pathways: improved body composition (more lean mass, less fat mass increases basal metabolic efficiency), enhanced recovery from physical and mental exertion, improved deep sleep architecture, and direct effects on cellular metabolism and protein synthesis. GH-deficient adults consistently report fatigue, reduced exercise capacity, and impaired quality of life -- symptoms that resolve with GH restoration.

The indirect evidence from GH-deficient adults treated with GH replacement consistently shows improvements in energy, exercise capacity, mood, and sleep quality. CJC-1295/Ipamorelin aims to achieve similar GH optimization through stimulating endogenous production rather than replacing it.

For dosing protocols and vendor comparisons, see the CJC-1295/Ipamorelin page.

5. MK-677 (Ibutamoren) -- Oral GH Secretagogue for Sleep and Recovery

MK-677 is the only orally active growth hormone secretagogue with clinical trial data demonstrating improved sleep architecture -- making it uniquely positioned for fatigue driven by poor sleep quality. Unlike injectable GH secretagogues, MK-677 requires no injections and can be taken as a single daily oral dose.

The sleep data is the most directly relevant to fatigue. In a clinical study, high-dose MK-677 treatment produced an approximately 50% increase in stage IV deep sleep duration and more than 20% increase in REM sleep compared to placebo. The frequency of sleep deviations from normal decreased from 42% under placebo to 8% under MK-677 treatment. In older adults, MK-677 increased REM sleep by nearly 50% and reduced REM latency. These are substantial improvements in the sleep stages most critical for physical recovery and cognitive restoration.

The GH axis effects parallel CJC-1295/Ipamorelin: MK-677 increased plasma IGF-I by 1.5-3 fold in a dose-dependent manner, with effects sustained over 12 months of treatment. Over that period, the ghrelin mimetic enhanced pulsatile GH secretion and significantly increased fat-free mass. Two months of treatment in obese subjects increased GH secretion, fat-free mass, and resting energy expenditure.

The practical advantages of MK-677 include oral dosing (no injections), once-daily administration (typically before bed to align GH release with natural nighttime GH pulse), and consistent clinical data across multiple trials. The main disadvantages are increased appetite (MK-677 activates ghrelin receptors, which stimulate hunger) and transient water retention during the first 2-4 weeks.

MK-677 is best suited for individuals whose fatigue is primarily sleep-related or who prefer oral dosing over injections. The appetite increase may be a benefit for underweight or malnourished individuals but is counterproductive for those also pursuing weight loss. For protocols and vendor comparisons, see the MK-677 page.

How to Choose: Match Peptide to Fatigue Type

The most common mistake with energy peptides is treating fatigue as a single problem. Different biological causes require different interventions.

Fatigue Type 1 -- Age-Related Mitochondrial Decline: Symptoms: gradual onset over years, worse with physical exertion, reduced exercise capacity, slow recovery from activity. The underlying problem is declining mitochondrial efficiency. Best approach: SS-31 (direct mitochondrial membrane stabilization) + NAD+ precursors (cofactor restoration). Add MOTS-c if metabolic inflexibility is a component.

Fatigue Type 2 -- Metabolic/Insulin-Resistance Fatigue: Symptoms: energy crashes after meals, brain fog, difficulty with sustained mental focus, associated with obesity or prediabetes. The underlying problem is impaired glucose metabolism and AMPK signaling. Best approach: MOTS-c (AMPK activation, glucose metabolism) + NAD+ precursors. Address insulin resistance as the root cause.

Fatigue Type 3 -- Sleep-Related Fatigue: Symptoms: unrefreshing sleep despite adequate hours, difficulty reaching deep sleep, frequent nighttime waking, daytime sleepiness. The underlying problem is disrupted sleep architecture. Best approach: MK-677 (50% increase in stage IV sleep, 20% increase in REM). Take before bed to align with natural GH pulse. CJC-1295/Ipamorelin as an injectable alternative with similar sleep benefits.

Fatigue Type 4 -- Hormonal/Recovery Fatigue: Symptoms: poor recovery from exercise, slow wound healing, decreased lean mass, generalized low energy without specific triggers. The underlying problem is GH/IGF-1 axis decline. Best approach: CJC-1295/Ipamorelin (most physiologic GH restoration) or MK-677 (oral convenience). Monitor IGF-1 levels to titrate dosing.

Mixed Fatigue (most common in adults 40+): Most real-world fatigue involves multiple mechanisms. The strongest combination: SS-31 or MOTS-c (mitochondrial) + CJC-1295/Ipamorelin or MK-677 (GH/sleep) + NAD+ precursors (cofactor). This three-layer approach addresses cellular energy production, hormonal optimization, and the cofactors bridging both systems.

Stacking Strategies

Mitochondrial Focus Stack: MOTS-c + NAD+ precursors (NR 500-1000 mg/day). MOTS-c activates AMPK and improves mitochondrial metabolism while NR provides the NAD+ cofactors that mitochondria consume. Add SS-31 for direct electron transport chain optimization if age-related decline is significant.

Sleep and Recovery Stack: MK-677 (before bed) + magnesium glycinate (400 mg). MK-677 improves deep sleep and REM architecture; magnesium supports GABA receptor function for sleep onset and maintenance. Do not combine MK-677 with CJC-1295/Ipamorelin -- they stimulate GH through overlapping pathways with diminishing returns when combined.

Full Spectrum Energy Protocol: MOTS-c or SS-31 (mitochondrial) + CJC-1295/Ipamorelin (GH optimization) + NR or NMN (NAD+ restoration). Three mechanisms, three intervention points, minimal overlap. This is the most comprehensive approach for multi-factorial fatigue in adults over 40.

Monitoring and Bloodwork

Energy peptide protocols benefit from objective biomarker tracking beyond subjective energy ratings.

• IGF-1: Primary marker for GH secretagogue response. Baseline plus every 6-8 weeks during CJC-1295/Ipamorelin or MK-677 protocols. Target: age-appropriate upper quartile, not supraphysiologic.
• Fasting glucose and insulin: Track metabolic improvement with MOTS-c and NAD+ protocols. Improving insulin sensitivity correlates with reduced metabolic fatigue.
• HbA1c: Three-month glycemic average. Relevant for metabolic fatigue presentations.
• Comprehensive metabolic panel: Monitor kidney and liver function during any peptide protocol.
• Thyroid panel (TSH, free T3, free T4): Rule out thyroid dysfunction as a fatigue cause before attributing fatigue to other mechanisms. Peptides will not fix hypothyroidism.
• Testosterone (total and free): In men, low testosterone is a common treatable fatigue cause that peptides do not address. Rule it out or treat it independently.

Related Reading

• MK-677 Dosing Guide
• CJC-1295/Ipamorelin Dosing Guide
• Best Peptides for Anti-Aging
• Best Peptides for Brain Health
• Best Peptides for Muscle Growth

References

1. Lee C, et al. The mitochondrial-derived peptide MOTS-c promotes metabolic homeostasis and reduces obesity and insulin resistance. Cell Metab. 2015;21(3):443-454. PMID: 25738459
2. Reynolds JC, et al. MOTS-c is an exercise-induced mitochondrial-encoded regulator of age-dependent physical decline and muscle homeostasis. Nat Commun. 2021;12(1):470. PMID: 33473109
3. Siegel MP, et al. Improving mitochondrial function with SS-31 reverses age-related redox stress and improves exercise tolerance in aged mice. Free Radic Biol Med. 2019;134:268-281. PMID: 30597195
4. Chiao YA, et al. Late-life restoration of mitochondrial function reverses cardiac dysfunction in old mice. eLife. 2020;9:e55513. PMID: 32648542
5. Di Meo I, et al. The mitochondrially targeted peptide elamipretide (SS-31) improves ADP sensitivity in aged mitochondria by increasing uptake through the adenine nucleotide translocator (ANT). GeroScience. 2023;45(6):3529-3541. PMID: 37462785
6. Dolopikou CF, et al. Acute nicotinamide riboside supplementation improves redox homeostasis and exercise performance in old individuals: a double-blind cross-over study. Eur J Nutr. 2020;59(2):505-515. PMID: 30725213
7. Martens CR, et al. Chronic nicotinamide riboside supplementation is well-tolerated and elevates NAD+ in healthy middle-aged and older adults. Nat Commun. 2018;9(1):1286. PMID: 29599478
8. Teichman SL, et al. Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults. J Clin Endocrinol Metab. 2006;91(3):799-805. PMID: 16352683